Maccura BiotechnologyLtd Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Wu Mingjian

Chief executive officer

CN¥1.3m

Total compensation

CEO salary percentage	n/a
CEO tenure	9.3yrs
CEO ownership	0.2%
Management average tenure	no data
Board average tenure	7.6yrs

Recent management updates

Recent updates

Even With A 38% Surge, Cautious Investors Are Not Rewarding Maccura Biotechnology Co.Ltd's (SZSE:300463) Performance Completely

Oct 08

Is Maccura BiotechnologyLtd (SZSE:300463) Using Too Much Debt?

Aug 01

Many Still Looking Away From Maccura Biotechnology Co.Ltd (SZSE:300463)

May 28

Some Investors May Be Willing To Look Past Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings

May 01

CEO

Wu Mingjian (47 yo)

9.3yrs

Tenure

CN¥1,314,000

Compensation

Mr. Wu Mingjian serves as General Manager of Maccura Biotechnology Co. Ltd and serves as its Director since August 14, 2015. He served as Commercial Director and Finance Manager at Maccura Biotechnology Co...

Board Members

Name	Position	Tenure	Compensation	Ownership
Wu Mingjian	GM & Director	9.3yrs	CN¥1.31m	0.24% CN¥ 21.2m
Shan Yin	CFO & Director	2yrs	CN¥843.60k	0.043% CN¥ 3.8m
Shengguo Xu	Director of Marketing & Director	7.2yrs	CN¥355.40k	0.027% CN¥ 2.4m
Daiguo Fu	Independent Director	5.8yrs	CN¥100.00k	no data
Hong Deng	Non-Employee Representative Supervisor	3yrs	no data	0.036% CN¥ 3.2m
Deng Ming Wang	Director	14.9yrs	CN¥733.80k	7.5% CN¥ 663.0m
Lin Wang	Employee Representative Supervisor	14.9yrs	no data	0.39% CN¥ 34.4m
Yong Tang	Chairman of the Board	14.9yrs	CN¥1.30m	11.22% CN¥ 991.0m
Yuan Zou	Chairman of Supervisor Board	8yrs	no data	0.20% CN¥ 17.8m
Qi Lin Liu	Director	14.9yrs	CN¥705.30k	5.46% CN¥ 482.3m
Kaicheng Liang	Independent Director	2.8yrs	CN¥100.00k	no data
Zhenzhong Liao	Independent Director	2.8yrs	CN¥100.00k	no data

7.6yrs

Average Tenure

55yo

Average Age

Experienced Board: 300463's board of directors are considered experienced (7.6 years average tenure).

Maccura BiotechnologyLtd Management

Management criteria checks 3/4

Key information

Recent management updates

Maccura Biotechnology Co.Ltd, Annual General Meeting, Jun 03, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.15 in 3Q 2023)

Even With A 38% Surge, Cautious Investors Are Not Rewarding Maccura Biotechnology Co.Ltd's (SZSE:300463) Performance Completely

Maccura Biotechnology Co.Ltd to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 30%

Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.095 in 2Q 2023)

Is Maccura BiotechnologyLtd (SZSE:300463) Using Too Much Debt?

Maccura Biotechnology Co.Ltd to Report First Half, 2024 Results on Aug 02, 2024

Maccura Biotechnology Co.Ltd Announces Final Profit Distribution Plan on A Shares for the Year 2023, Payable on July 3, 2024

Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2023

Many Still Looking Away From Maccura Biotechnology Co.Ltd (SZSE:300463)

Maccura Biotechnology Co.Ltd, Annual General Meeting, Jun 03, 2024

Some Investors May Be Willing To Look Past Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings

Maccura Biotechnology Co.Ltd Proposes Final Cash Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.19 in 1Q 2023)

Maccura Biotechnology Co.Ltd to Report Q1, 2024 Results on Apr 25, 2024

Maccura Biotechnology Co.Ltd (SZSE:300463) announces an Equity Buyback for CNY 100 million worth of its shares.

Investor sentiment deteriorates as stock falls 19%

Maccura Biotechnology Co.Ltd to Report Fiscal Year 2023 Results on Apr 25, 2024

Maccura Biotechnology Co.Ltd(SZSE:300463) dropped from Shenzhen Stock Exchange Component A Share Index

Consensus EPS estimates fall by 12%

Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.32 in 3Q 2022)

Consensus EPS estimates fall by 17%

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.095 (vs CN¥0.33 in 2Q 2022)

Maccura Biotechnology Co.Ltd to Report First Half, 2023 Results on Jul 29, 2023

Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2022

Price target decreased by 21% to CN¥20.86

First quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.34 in 1Q 2022)

Price target increased to CN¥26.33

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.32 (vs CN¥0.48 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.39 in 2Q 2021)

Maccura Biotechnology Co.Ltd Approves Cash Dividend for 2021

Maccura Biotechnology Co.Ltd Approves Cash Dividend of for 202

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 18%

Less than half of directors are independent

Maccura Biotechnology Co.Ltd Proposes Final Dividend for the Year 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.48 (vs CN¥0.46 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.42 in 2Q 2020)

Maccura Biotechnology Co.Ltd Approves Final Dividend for the Year 2020

Maccura Biotechnology Co.Ltd Proposes Final Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.14 in 1Q 2020)

Maccura Biotechnology Co.Ltd (SZSE:300463) announces an Equity Buyback for CNY 300 million worth of its shares.

New 90-day low: CN¥39.84

New 90-day low: CN¥41.24

New 90-day low: CN¥45.38

Price target raised to CN¥62.32

Third quarter earnings released

Maccura Biotechnology Co.Ltd announced that it expects to receive CNY 2.77 billion in funding

Maccura Biotechnology Co.Ltd to Report First Half, 2020 Results on Jul 31, 2020

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age